Clinical trial NCT04827875: Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy
Official title: An Exploratory Study to Evaluate the Safety and Efficacy of Intradermal Administration of AIV001 Aqueous Suspension on Scar Formation and Keloid Recurrence Following Keloidectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Keloid
Scar
Incision
Excision Margin
Keywords: Scar formation
Keloidectomy
Lead sponsor: AiViva BioPharma, Inc.
Sponsor class: INDUSTRY
First posted: 2021-04-01
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Excisions of existing keloid scar, treatment of incisional area followed by evaluation of scar formation overtime.
Primary purpose: PREVENTION

Brief summary: To evaluate the saftye and effectiveness of AIV001 treatment on scar formation and/or keloid scar recurrence following keloidectomy.

Detailed description: AIV001 (axitinib) has been formulated to provide focal disease-modifying therapy for patients undergoing surgical procedures where scar formation will occur. This was a multicenter, dose-escalation open label study to assess the safety and efficacy of AIV001 on scar formation and/or keloid recurrence following keloidectomy. This study design is an evaluation of surgical excision of keloid scar tissue followed by AIV001 intradermal injection. On Day 1, following keloidectomy, the incision area (devoid of keloid scar tissue) was sutured, creating an incision line. The incision line is the area of scar formation and assessment. This is a variable dose study defined by incision line length. The incision line length measurement defined each subject's AIV001 treatment based on the dose plan table in the protocol. Subjects received a minimum of 1 and up to 3 treatments, dependent on the protocol amendment implemented at the time of their participation and PI discretion based upon safety assessments. The excised tissue was sent to pathology for confirmation of keloid scar tissue. The treatment interval was Day 1 to Day 30 visits with observation visits on Days 60, 90, 183, and 365. A safety data review was conducted after the first 3 subjects in Cohort 1 completed the Day 30 visit. Assessment of local skin reactions (LSRs), wound healing, vitals, treatment-emergent adverse events (TEAEs) and pre-defined dose-limiting toxicities (DLTs) were reviewed to determine whether additional subjects were permitted to be enrolled. If safety was deemed acceptable, enrollment into Cohort 1 continued and Cohort 2 was open for enrollment. The same safety data review was conducted at Day 30 visit for the first 3 subjects enrolled in Cohort 2. The open-label study design allowed for adjustments to the dosing regimen (timing and frequency of dosing) based on review of each consecutive dosing cohort.

Eligibility criteria: Inclusion Criteria:

* Male of female, aged 18 to 60, inclusive
* No clinically relevant abnormalities identified by a detailed medical history and vital signs
* Presence of one keloid scar, up to 2.2 cm length and up to 1.2 cm width, at least 1 year from formation, and located on trunk or arms
* Willing to undergo surgical excision of keloid
* No concurrent treatment of the study keloid or prior treatment within last 2 months

Exclusion Criteria:

* Prior keloidectomy of study keloid
* History of genetic disorder that predisposes to keloids (e.g., Ehlers-Danlos syndrome, Ullrich congenital muscular dystrophy, etc.)
* Corticosteroids (topical, injectable, inhalable, intranasal, or oral) within last two months (except as prescribed by physician for seasonal allergies)
* Clinically relevant cardiovascular, endocrine, hepatic, neurologic, renal, or other major systemic disease that could complicate execution of the protocol or interpretation of the study results
* History of thrombotic events, hemorrhagic events, and gastrointestinal perforation and fistula
* Subject has active collagen vascular disease or vasculitis, e.g., systemic lupus erythematosus, polyarthritis, dermatomyositis, systemic scleroderma or thrombotic thrombocytopenic purpura

Primary outcomes:
measure: Adverse events
timeFrame: Approximately 365 days
Secondary outcomes:
measure: Keloid recurrence
timeFrame: 365 days
measure: Modified Vancouver Scar Scale (mVSS)
timeFrame: Day 90 and Day 180
Other outcomes:
Locations:
city: Encinitas
country: United States
facility: California Dermatology & Clinical Research Institute
state: California
city: Coral Gables
country: United States
facility: Skin Research Institute
state: Florida
city: Austin
country: United States
facility: DermResearch DRI
state: Texas
city: College Station
country: United States
facility: J&S Studies
state: Texas
Study officials:
References: